Press release - 26/01/2021 Report on the Mapping of Biomass Value Chains for Improved Sustainable Energy use in the Baltic Sea Region Countries Published The University of Warmia and Mazury in Olsztyn, Polish partner of the BalticBiomass4Value project, published a report which maps biomass value chains for improved sustainable energy use in the Baltic Sea Region countries. The research focuses on the 9 Baltic Sea Region (BSR) countries: Denmark, Germany, Estonia, Finland, Latvia, Lithuania, Poland, Sweden, and Norway.https://www.biooekonomie-bw.de/en/articles/pm/report-mapping-biomass-value-chains-improved-sustainable-energy-use-baltic-sea-region-countries-published
Event - 05/02/2021 Startup Funding Day online, Informationsveranstaltung https://www.bio-pro.de/en/events/past-events/startup-funding-day
Press release - 25/01/2021 Protein anchors as a newly discovered key molecule in cancer spread and epilepsy Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-anchors-newly-discovered-key-molecule-cancer-spread-and-epilepsy
Event - 16/02/2021 Alpine Policy Forum online (Cisco Webex), Registration deadline: 09/02/2021, Kongress/Symposium https://www.bio-pro.de/en/events/past-events/alpine-policy-forum
Paper production from plant fibres - 20/01/2021 In one cycle: ecopaper, energy and fertiliser made from Silphium perfoliatum Many consumers don't care about exactly how their paper packaging is made and what it is made of as long as it is "eco". But even producing recycled paper, trees need to be felled. An alternative could be paper made from cup plant. Together with partners, a company called Silphie Paper has developed concept for obtaining fibres for a new type of grass paper, while also producing heat, energy and nutrients for natural fertilisers.https://www.biooekonomie-bw.de/en/articles/news/one-cycle-ecopaper-energy-and-fertiliser-made-silphium-perfoliatum
Press release - 18/01/2021 How a protein variant could explain resistance to sleeping sickness drug A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-protein-variant-could-explain-resistance-sleeping-sickness-drug
Biobased building materials - 14/01/2021 Chitin for the development of sustainable materials for use in the construction and other industries Pliable and robust, light and stable - it sounds like an ideal material for the construction and many other industries. A team of researchers at the University of Stuttgart is researching what purposes the naturally good properties of chitin can serve.https://www.biooekonomie-bw.de/en/articles/news/Chitin-for-the-development-of-sustainable-materials-for-use-in-the-construction-and-other-industries
Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Overview Completed projects Hier werden die abgeschlossenen Projekte gesammelt.https://www.bio-pro.de/en/projects/Completed-projects
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Infection control - 07/01/2021 Gene accordions as potential markers for pathogenic properties Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.https://www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
Press release - 04/01/2021 Fungus as a sound absorber As healthy and tasty as mushrooms might be, they are good for much more than just the dinner plate. The Fraunhofer Institute for Environmental, Safety and Energy Technology UMSICHT has now teamed up with the Fraunhofer Institute for Building Physics IBP to investigate the use of fungus-based materials for the fabrication of eco-friendly sound absorbers.https://www.biooekonomie-bw.de/en/articles/pm/Fungus-as-a-sound-absorber
Natural substance with herbicide potential - 10/12/2020 The same but different: What makes sugar 7Sdh a better herbicide? The sugar 7-deoxy-sedoheptulose (7dSh) is produced by cyanobacteria and inhibits the same metabolic pathway as the broad-spectrum herbicide glyphosate, thus making it an excellent herbicide candidate. Despite this amazing similarity, the microbiologist who discovered 7dSh, Prof. Dr. Karl Forchhammer, believes that this sugar has clear ecological advantages over glyphosate.https://www.biooekonomie-bw.de/en/articles/news/The-same-but-different-what-makes-sugar-7Sdh-a-better-herbicide
Digitalisation in Medicine - 08/12/2020 DiHeSys takes steps towards application Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.https://www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Outlook on the future of agriculture - 30/11/2020 Agriculture 4.0 - ultramodern and without harmful plant protection products The demand for organic products is continuing to grow; at the same time nature is being preserved – so why not switch completely to organic farming? The answer is simple: because not everyone can afford it, and with current consumption patterns not everyone would get enough to eat. A cooperative project is researching an an agricultural system that falls between conventional and organic farming.https://www.biooekonomie-bw.de/en/articles/news/Agriculture-4-0-ultramodern-and-without-harmful-plant-protection-products
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Development of biogenic packaging - 16/11/2020 Sustainable packaging - the devil is in the detail Modern packaging often boils down to a tick list of biogenic origin and/or biodegradability. But comprehensive sustainable packaging concepts need more than just that. Perishable foods, for example, require special barrier properties. The Albstadt-Sigmaringen University of Applied Sciences is researching packaging concepts for their sustainability.https://www.biooekonomie-bw.de/en/articles/news/sustainable-packaging-devil-detail
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Dossier - 09/11/2020 Packaging of the future What will the packaging of the future look like, and what will be required of it? Can packaging be biobased, recyclable, sustainable and economic? In Baden-Württemberg, there are various approaches to developing packaging with the above properties from various sources including agricultural residual and side streams as well as municipal waste.https://www.biooekonomie-bw.de/en/articles/dossiers/packaging-future
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Inside the fight against COVID-19 - 28/10/2020 A new immunotherapeutic agent for treating severe COVID-19 cases Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
Funding European Circular Bioeconomy Fund Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investorshttps://www.bio-pro.de/en/database/funding/european-circular-bioeconomy-fund
Funding European Circular Bioeconomy Fund Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investorshttps://www.biooekonomie-bw.de/en/databases/funding/european-circular-bioeconomy-fund
Phosphorus recovery from sewage sludge - 21/10/2020 Bacteria help to recycle phosphorus Biotechnology for the bioeconomy: in something known as the P-bac process, sulphur bacteria extract phosphorus from sewage sludge ash. Phosphorus is one of the key building blocks of life and an essential nutrient for plant growth. When there is not enough phosphorus in the soil, farmers apply it via organic or mineral fertilisers.https://www.biooekonomie-bw.de/en/articles/news/bacteria-help-recycle-phosphorus
Atriva Therapeutics - 21/10/2020 COVID-19 pioneer drug in Phase II clinical trial - with double the power The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
Intestinal peptide heals lung - 14/10/2020 Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
KyooBe Tech GmbH - 08/10/2020 Next generation vaccine production For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
Life Science job fair - 28/04/2021 CONTACT2021 Heidelberghttps://www.bio-pro.de/en/events/past-events/contact2021
Freudenberg Filtration Technologies - 01/10/2020 Coronavirus thwarted: with filters against aerosol spread Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.https://www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
Organ failure due to fatty liver - 24/09/2020 HepaRegeniX develops an active substance for liver regeneration When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure. https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
Event - 03/11/2020 Building a Sustainable Network for Smart SMEs in the Alpine Region Online event, Registration deadline: 16/10/2020https://www.bio-pro.de/en/events/past-events/building-sustainable-network-smart-smes-alpine-region
Mosses for pharmaceutical production - 16/09/2020 Factor H as a therapeutic option for viral diseases - including COVID-19 The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
Phytopharmaceuticals - 14/09/2020 Medicinal cannabis to be grown in Germany Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
Biochip systems - 02/09/2020 Miniature organs with great potential Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
Innovative Therapies - 20/08/2020 Labor Dr. Merk is fully committed to viral therapies Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
CeGat GmbH - 06/08/2020 CeGaT: Specific coronavirus antibody test for all Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
Event - 26/08/2020 - 27/08/2020 Global Cluster Partnering - Healthcare onlinehttps://www.bio-pro.de/en/events/past-events/global-cluster-partnering-healthcare
TGU Varimol - 24/07/2020 Click chemistry for new medical procedures Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
Microstructure Technology - 17/07/2020 An electronic nose for many applications Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Qualitative soil fertiliser - 10/07/2020 How natural cycles can be closed with wood ash Recycled material instead of waste: wood ash is good for soil and plants - if the quality is right. The German Federal Quality Association for Food Ash ensures reliable wood ash standards with its certifications. The RAL-Dünger label for fertilisers provides the necessary certification for natural wood ashes to be used in the circular economy.https://www.biooekonomie-bw.de/en/articles/news/how-natural-cycles-can-be-closed-wood-ash
Review article (new edition) - 08/07/2020 Immunology – at the forefront of medical progress Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress
Affimed GmbH - 01/07/2020 "Innate cell engager" fighting against cancer In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.https://www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
rezemo GmbH - 26/06/2020 Coffee capsules: wood instead of aluminium In Germany alone, around three billion disposable coffee capsules made of aluminium and plastic are sold every year. This creates a gigantic waste problem, as only a small proportion of the capsules can be recycled. Fully compostable wooden coffee capsules might be a solution to this problem. The capsules have been developed by a start-up company called rezemo, which also has other biobased packaging solutions in the pipeline.https://www.biooekonomie-bw.de/en/articles/news/coffee-capsules-wood-instead-aluminium
SICOS BW GmbH - 18/06/2020 High-performance computing and data analytics to combat coronavirus In an epidemic, data exchange and the use of innovative technologies are essential to be able to act effectively and quickly against the infection. High-performance computers and data analytics make a valuable contribution to this. SICOS BW is a promising solution centre that bridges the gap from numerical simulation, big data and AI to companies in the medical technology sector.https://www.gesundheitsindustrie-bw.de/en/article/news/high-performance-computing-and-data-analytics-to-combat-coronavirus
Perspectives of methane as energy source - 18/06/2020 New technologies for using biogas as a balancing energy The microorganisms in biogas plants do a great job biologically converting CO₂ and hydrogen, which are primary fermentation products, into methane. Biomethane has a great future as an energy source. Scientists at the University of Hohenheim are investigating new ways to produce and use biomethane.https://www.biooekonomie-bw.de/en/articles/news/new-technologies-for-using-biogas-as-balancing-energy
Innovations in the field of endoscopy - 08/06/2020 Gastroscopies with pill cameras A pill camera to examine the gastrointestinal tract that can be swallowed without major difficulty, controlled intuitively from the outside and deliver images in real time - why would any doctor or patient say no? To non-experts, it sounds more like science fiction but such a device is actually already in development: since 2019, Tübingen-based Ovesco Endoscopy AG and three partners have been working together on this in a project called nuEndo.https://www.gesundheitsindustrie-bw.de/en/article/news/magenspiegelung-kamerapille
Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff